On the Pharmacology of Farnesoid X Receptor Agonists: Give me an “A”, Like in “Acid”
The Farnesoid X Receptor (FXR) has recently moved into the spotlight through the release of clinical data using Obeticholic Acid, an FXR agonist, that demonstrated effectiveness of this bile acid-like drug in patients with Primary Biliary Cirrhosis and Non-alcoholic Steatohepatitis (NASH). FXR holds...
Main Authors: | Eva Hambruch, Olaf Kinzel, Claus Kremoser |
---|---|
Format: | Article |
Language: | English |
Published: |
KenzPub
2016-06-01
|
Series: | Nuclear Receptor Research |
Subjects: | |
Online Access: | http://www.kenzpub.com/journals/nurr/2016/101207/ |
Similar Items
-
Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
by: Sun-Gi Kim, et al.
Published: (2016-12-01) -
Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
by: Ludovico Abenavoli, et al.
Published: (2020-06-01) -
Role of farnesoid X receptor and bile acids in alcoholic liver disease
by: Sharon Manley, et al.
Published: (2015-03-01) -
(E)-7-Ethylidene-lithocholic Acid (7-ELCA) Is a Potent Dual Farnesoid X Receptor (FXR) Antagonist and GPBAR1 Agonist Inhibiting FXR-Induced Gene Expression in Hepatocytes and Stimulating Glucagon-like Peptide-1 Secretion From Enteroendocrine Cells
by: Alzbeta Stefela, et al.
Published: (2021-08-01) -
Gypenosides regulate farnesoid X receptor-mediated bile acid and lipid metabolism in a mouse model of non-alcoholic steatohepatitis
by: Hongshan Li, et al.
Published: (2020-05-01)